1. Home
  2. NKGN vs ACXP Comparison

NKGN vs ACXP Comparison

Compare NKGN & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NKGN
  • ACXP
  • Stock Information
  • Founded
  • NKGN 2017
  • ACXP 2017
  • Country
  • NKGN United States
  • ACXP United States
  • Employees
  • NKGN N/A
  • ACXP N/A
  • Industry
  • NKGN Biotechnology: Biological Products (No Diagnostic Substances)
  • ACXP Biotechnology: Pharmaceutical Preparations
  • Sector
  • NKGN Health Care
  • ACXP Health Care
  • Exchange
  • NKGN Nasdaq
  • ACXP Nasdaq
  • Market Cap
  • NKGN 24.1M
  • ACXP 33.9M
  • IPO Year
  • NKGN N/A
  • ACXP 2021
  • Fundamental
  • Price
  • NKGN $1.11
  • ACXP $2.54
  • Analyst Decision
  • NKGN
  • ACXP Strong Buy
  • Analyst Count
  • NKGN 0
  • ACXP 1
  • Target Price
  • NKGN N/A
  • ACXP $12.00
  • AVG Volume (30 Days)
  • NKGN 1.9M
  • ACXP 71.2K
  • Earning Date
  • NKGN 08-16-2024
  • ACXP 08-12-2024
  • Dividend Yield
  • NKGN N/A
  • ACXP N/A
  • EPS Growth
  • NKGN N/A
  • ACXP N/A
  • EPS
  • NKGN N/A
  • ACXP N/A
  • Revenue
  • NKGN N/A
  • ACXP N/A
  • Revenue This Year
  • NKGN N/A
  • ACXP N/A
  • Revenue Next Year
  • NKGN N/A
  • ACXP N/A
  • P/E Ratio
  • NKGN N/A
  • ACXP N/A
  • Revenue Growth
  • NKGN N/A
  • ACXP N/A
  • 52 Week Low
  • NKGN $0.78
  • ACXP $1.17
  • 52 Week High
  • NKGN $6.70
  • ACXP $8.82
  • Technical
  • Relative Strength Index (RSI)
  • NKGN 45.52
  • ACXP 61.18
  • Support Level
  • NKGN $0.87
  • ACXP $1.99
  • Resistance Level
  • NKGN $1.37
  • ACXP $2.57
  • Average True Range (ATR)
  • NKGN 0.12
  • ACXP 0.21
  • MACD
  • NKGN -0.02
  • ACXP 0.05
  • Stochastic Oscillator
  • NKGN 47.70
  • ACXP 41.20

About NKGN NKGen Biotech Inc.

NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.

Share on Social Networks: